Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629208 · ClinicalTrials.gov registry record · Phase 2
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05629208 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 20 participants.
The verdict
NCT05629208, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Interventions
- DRUG Edecesertib
- DRUG Edecesertib Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2026-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05629208
The ClinicalTrials.gov registry entry for NCT05629208 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Edecesertib is the first listed.
NCT05629208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05629208 about?
NCT05629208 is a clinical study titled "Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)". The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the stud...
What is the current status of trial NCT05629208?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-04-17. Estimated completion is 2026-01-14.
What interventions are being tested in trial NCT05629208?
The interventions under investigation include: Edecesertib (DRUG), Edecesertib Placebo (DRUG).
Who is sponsoring clinical trial NCT05629208?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.